(Q36763997)

16 August 2017

1 reference

title

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy (English)

1 reference

16 August 2017

Karen Bush

1

1 reference

16 August 2017

Markus Heep

series ordinal

2

1 reference

16 August 2017

Mark J Macielag

series ordinal

3

1 reference

16 August 2017

Gary J Noel

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

419-429

1 reference

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Ceftobiprole: in-vivo profile of a bactericidal cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

SM-216601, a novel parenteral 1beta-methylcarbapenem: structure-activity relationships of antibacterial activity and neurotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.419

10.1517/13543784.16.4.419

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference